## AURO LABORATORIES LIMITED CIN NO. :- L33125MH1989PLC051910

Regd. Office: K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR BOISAR, DIST. PALGHAR 401506, MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Website: www.aurolabs.com

## ANNEXURE - I

	STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUAR	RTER ENDED 30T	H JUNE 2019		
		3 Months ended	Preceding 3	Corresponsing 3 Months ended in the Previous Year	For the yer Ended
Sr.		30.06.2019	31.03.2019	30.06.2018	31.03.2019
No.	Particulars	(Unaudited)	(audited)	(Unaudited)	(Audited)
1	Income from Operations				
	(a) Net Sales/Income from Operations (Net of GST)	1,371.56	1153.015	1,046.78	4,682.31
2	Other Income	25.90	59.34	3.09	95.82
3	Total Revenue (1 + 2)	1,397.46	1,212.36	1,049.87	4,778.13
4	Expenses				
	a. Consumption of raw material	1,029.59	621.14	716.41	3,013.82
	b. Purchase of Stock-in-trade	24.10	23.87	1.04	24.91
	c (Increase) / decrease in Finished Goods stock	(127.81)	(8.65)	(65.90)	(176.59
	in trade and work in progress		(4.1.2)	3,333,	
	d. Employee benefits expense	102.65	132.32	86.65	407.07
	e. Finance Cost	15.52	12.57	22.80	72.22
	f. Depreciation and amortisation expenses	25.00	22.42	24.50	100.92
	g. Other Expenses	176.09	177.535	179.61	728.89
	Total Expenses (4)	1,245.14	981.21	965.11	4,171.24
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 $\pm$ 4)	152.32	231.15	84.76	606.89
6	Exceptional items			16	
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)	152.32	231.15	84.76	606.89
8	Extraordinary items		- 2		
9	Profit / (Loss) before tax (7 ± 8)	152.32	231.15	84.76	606.89
10	Tax expense			-	
	(a) Current tax expesnes for current year	41.89	67.76	21.19	161.69
	(b) MAT credit (where applicable)				
	(c) Defferered tax		5.25	14	5.25
11	Profit / (Loss) for the period from continuing operation (9± 10)	110.43	158.15	63.57	439.95
12	Profit / (Loss) for discontinuing operations		7.6	141	
13	Tax expense of discontinuing operations	× =	( <del>*</del> )	(*)	
14	Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)	110.43	158.15	63.57	439.95
15	Other Comprehensive Income	10.68	8.11	17.92	8.11
16	Total Comprehensive Income for the period (14 ± 15)	121.11	166.26	81.49	448.06
17	Paid-up equity share capital	623.25	623.25	623.25	623.25
	(Face value of Rs. 10 each)				
18	Reserves excluding Revaluation Reserves as	•			1,117.95
	per balance sheet of previous accounting year)				
19	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):				
	(a) Basic	1.77	2.54	1.02	7.06
	(b) Diluted	1.77	2.54	1.02	7.06

## Notes

- The above unaudtied financial results for the quarter ended 30th June, 2019 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 07th August 2019.
- The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 3) Figures for the quarter ended March 31, 2019 are the balanceing figures between the audited figures in respect of the full financial year and the published year to date figures of nine months ended December 31, 2018.
- 5) Limited review has been carried out by the Statutory Auditors of the Company.
- 6) Figures of previous period have regrouped / reclassfied whereever necessary to facilitate comparison.

FOR & BEHALF OF THE BOARD OF DIRECTORS

AURO LABORATORIES LIMITED

SHARAT DEORAH

CHAIRMAN & MANAGING DIRECTOR

DIN NO. 00230784

Place : Mumbai Date : 07.08.2019



To,
The Board of Directors,
Auro Laboratories Limited.

We have reviewed the accompanying unaudited standalone Ind AS financial results of Auro Laboratories Ltd. ("the company") for the quarter ended June 30, 2019, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019.

The preparation of the statement in accordance with the recognition measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, as amended, read with the Circular is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company in their meeting held on 7th August, 2019. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements prepared in all material respects in accordance with the Ind AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019, including the manner in which it is to be disclosed or that it contains any material misstatement.

For Khurdia Jain & Co.

Chartered Accountants Firm Reg. No. 120263W

Harekme

Sampat Khurdia

Partner

Membership No. 033615

Place: Mumbai

Date: 7th August, 2019

UDIN NO.19033615AAAACB4706